TSC-100, TSC-101 - (ALLOHA)

June 22, 2026: TScan Therapeutics, Inc. (NASDAQ: TCRX) presented data from Cohort C of the ongoing ALLOHA™ Phase 1 study of TSC-101 (made using a commercial-ready manufacturing process) in patients with hematologic malignancies undergoing allogeneic hematopoietic cell transplantation (allo-HCT), aimed at preventing relapse post-transplant. Nineteen patients were enrolled; manufacturing success was ~90% (17/19). Fourteen patients proceeded to transplant and received a first TSC-101 infusion; 10/14 received a planned second infusion and 1/14 received a third; 3/19 did not proceed to transplant for clinical reasons.

Using a high-sensitivity NGS chimerism assay (Alloheme; 0.2% cutoff), 11/14 patients achieved complete donor chimerism within ~3 weeks after the first infusion, and 2 additional patients showed improving/approaching complete chimerism; all 5 patients assessed after a second infusion had complete chimerism. One TP53-mutated AML patient remained in complete donor chimerism 6 months post-HCT. TSC-101 was generally well-tolerated, with safety consistent with Cohort A and adverse events consistent with post-HCT events.

The company said it remains on track to enroll the first patient this month in the pivotal Phase 3 ALLOHA-2™ study of TSC-101, and will host a virtual KOL event on June 22, 2026 at 8:30 a.m. ET.